Home / Companies / News / Double whammy: Power brands give Sanofi revenues and an edge over peers

Double whammy: Power brands give Sanofi revenues and an edge over peers

One-time dividend of Rs 243 has given a leg up to sentiment

Premium

2 min read Last Updated : Feb 27 2020 | 2:24 AM IST

The Sanofi India stock hit fresh highs on Wednesday, after it posted a better-than-expected December quarter (Q3) performance.

Revenue growth continues to be driven by a large branded portfolio in the high-growth chronic segment. The tilt towards the more-profitable chronic segment, coupled with a leadership position in diabetes therapy, gives it an edge over its peers.

Revenues in Q3 grew 14 per cent year-on-year (YoY). The top five products have contributed about 57 per cent to revenues, and are likely to drive future growth, say analysts. Top brands like Lantus for diabetes, Allegra an anti-allergic, and Combiflam for pain relief

Topics : Sanofi India

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in